Please login to the form below

Not currently logged in
Email:
Password:

insulin aspart

This page shows the latest insulin aspart news and features for those working in and with pharma, biotech and healthcare.

Novo follows Sanofi, Lilly with insulin price cut in US

Novo follows Sanofi, Lilly with insulin price cut in US

The Danish drugmaker says it will offer an authorised generic version of NovoLog (insulin aspart) at around $145 per vial, roughly half the branded drug’s current US list price, from ... which offered a 50% cheaper version of its Humalog (insulin lispro

Latest news

  • Novo Nordisk preps for speedy oral GLP-1 drug filing Novo Nordisk preps for speedy oral GLP-1 drug filing

    10% gain for Tresiba (insulin degludec) and a sharp increase for Xultophy, a combination insulin/GLP-1 shot which more than doubled to 1.6bn krone. ... Novo’s CEO Lars Fruergaard Jørgensen. New fast-acting mealtime insulin Fiasp (insulin aspart),

  • Gilead's hepatitis B virus treatment set for European approval Gilead's hepatitis B virus treatment set for European approval

    The dual-therapy works to reduce high blood glucose while enhancing glucose-dependent insulin secretion and reducing glucagon release. ... Meanwhile, Novo Nordisk looks set to add Fiasp (insulin aspart) to its diabetes drug stable, as the fast-acting

  • Novo Nordisk's Tresiba gaining ground in basal insulin market Novo Nordisk's Tresiba gaining ground in basal insulin market

    Sales of Novo Nordisk's new basal insulin product Tresiba have started to gather momentum since its US launch in January, rising three-fold in the first half of the year. ... Nevertheless, the strong sales performance for Tresiba and other new insulin

  • Tresiba safer than insulin glargine, says Novo Nordisk Tresiba safer than insulin glargine, says Novo Nordisk

    Moreover, it could also differentiate Tresiba from biosimilar copies of Sanofi's drug that are starting to reach the market and threaten to disrupt the basal insulin category. ... Last October however the Danish drugmaker finally won US approval for

  • Novo Nordisk finally bags insulin degludec approval in US Novo Nordisk finally bags insulin degludec approval in US

    Long-acting basal insulin Tresiba (insulin degludec) and combination drug Ryzodeg (insulin degludec and insulin aspart) will now be able to compete head-to-head in the market with Sanofi's ... that the drug – along with Ryzodeg and Xultophy (insulin

More from news
Approximately 2 fully matching, plus 21 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Syneos Health™

Syneos Health™ is the only fully integrated biopharmaceutical solutions organization. Our company, including a Contract Research Organization (CRO) and Contract...

Latest intelligence

Switzerland
Switzerland: a life sciences hub
Switzerland has a rich diversity of pharma and biotech companies that sustain activity and help maintain its reputation as a highly innovative country...
Responding to dynamic shifts in value communications
OPEN Health’s Beth Lesher and Annemarie Clegg examine what the convergence of medical communications and market access means for pharmaceutical companies....
Doing what we can and having fun doing it: our fundraising month
Charities are facing a number of challenges just to stay afloat amidst the current COVID-19 pandemic. Fundraisers are being cancelled and public donations are not as abundant as they have...

Infographics